Circulating tumor cell enumeration in men with mCRPC receiving xaluritamig

Andrew Armstrong, MD, Duke Cancer Institute, Durham, NC, comments on the first-in-human dose exploration trial (NCT04221542) of xaluritamig, a novel STEAP1 x CD3 bispecific T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor cell (CTC) conversion and PSA declines were shown to correlate with prolonged survival. These results support further validation of xaluritamig and the potential of CTC monitoring to predict treatment benefit. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.